Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study

BACKGROUND: Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies. METHODS: ABitude is an Italian, observational, prospective, multicenter stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Procopio, Giuseppe, Chiuri, Vincenzo Emanuele, Giordano, Monica, Mantini, Giovanna, Maisano, Roberto, Bordonaro, Roberto, Calvani, Nicola, Facchini, Gaetano, De Placido, Sabino, Airoldi, Mario, Sbrana, Andrea, Gasparro, Donatello, Ludovico, Giuseppe Mario, Guglielmini, Pamela, Naglieri, Emanuele, Fagnani, Daniele, Aglietta, Massimo, Schips, Luigi, Beccaglia, Patrizia, Sciarra, Alessandro, Livi, Lorenzo, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604981/
https://www.ncbi.nlm.nih.gov/pubmed/33193831
http://dx.doi.org/10.1177/1758835920968725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604981/
https://www.ncbi.nlm.nih.gov/pubmed/33193831
http://dx.doi.org/10.1177/1758835920968725

Ejemplares similares